

Program: Best of ASCO Bangkok 2018 (Day 1: 3 August 2018)

Time	Abstract ID	Title	Presenter	Moderator
7.30-8.30	Trainee session (Thai language)	Personalized Approach to Systemic Therapy of Renal Cancer	<i>Assist Prof. CHANYOOT BANDIDWATTANAWONG KULATIDA MANEENIL, M.D. NATTAYA POOVORAWAN, M.D.</i>	<i>Assoc.Prof.CHAIYUT CHAROENTUM</i>
8:30-9:30	Trainee session (Thai language)	Point/Counterpoint: Next-Generation Sequencing—Is It Right for Every Patient?	<i>Asst.Prof.SUEBPONG TANASANVIMON PONGWUT DANCHAIVICHITR, M.D.</i>	<i>Assoc.Prof.VIOTE SRIURANPONG</i>
9:30-9:40		Opening and welcome message Scientific Agenda		<i>Assoc.Prof.VIOTE SRIURANPONG</i> <i>Assoc.Prof.SUTHINEE ITHIMAKIN</i>
9:45-10:30		Symposium Amgen: How to optimize treatment outcome in RAS WT mCRC in first line setting : A key learning from expert	<i>Assoc.Prof. PETER GIBBS, MBBS, FRACP, MD, Walter and Eliza Hall Institute and Western Hospital, Melbourne, Australia</i>	<i>Asst.Prof.SUEBPONG TANASANVIMON</i>
10:30-10:50		Exhibition		
		Colorectal cancer session		
10:50-11:00	3501	Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer.	<i>Assist.Prof. KRITTIYA KORPHAISARN</i>	<i>Prof.VORACHAI RATANATHARATHORN</i>
11:00-11:10	3505	First-line FOLFOX plus panitumumab followed by 5FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.	<i>KULATIDA MANEENIL, M.D.</i>	
11:10-11.20	LBA3503	A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.	<i>Assist.Prof.KRIT KITISIN</i>	
11:20-11:40		Discussion/ Q&A	<i>Discussant: Prof.PETER GIBBS, Q&A: panelists</i>	
11:45-12:30		Symposium Novartis: Management in HR+ breast cancer	<i>Prof.JOO HYUK SOHN, M.D.PH.D. Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Korea</i>	<i>Assoc.Prof.CHAIYUT CHAROENTUM</i>
12:30-12:50		Exhibition		
		Breast cancer session		
12:50-13:00	LBA1	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptorpositive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score.	<i>Assist.Prof.THITIYA DEJTHEVAPORN</i>	<i>Assoc. Prof. VICHIEEN SRIMUNINNIMIT</i>
13:00-13:10	500	Adjuvant denosumab in early breast cancer: Disease free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.	<i>Assoc.Prof.SUTHINEE ITHIMAKIN</i>	

Program: Best of ASCO Bangkok 2018 (Day 1: 3 August 2018)

Time	Abstract ID	Title	Presenter	Moderator
13:10-13:20	502	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study.	<i>Assoc.Prof.PATRAPIM SUNPAWERAVONG</i>	
13:20-13:40		Discussion/ Q&A	<i>Discussant: Assist.Prof.AUMKHAE SOOKPRASERT, Q&A: panelists</i>	
13:40-13:50	506	PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 noninferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.	<i>Assist.Prof.AUMKHAE SOOKPRASERT</i>	
13:50-14:00	1000	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3	<i>PIYAWAN TIENCHAIANANDA, M.D.</i>	
14:00-14:10	LBA1006	Phase III study of taselelisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer: Primary analysis from SANDPIPER	<i>NAPA PARINYANITIKUL, M.D.</i>	
14:10-14:30		Discussion/ Q&A	<i>Discussant: Prof.ADAM BRUFSKY, Q&A: panelists</i>	
14:35-15:20		Symposium Roche: The expanding frontier with CIT in lung cancer	<i>Prof.Dae Ho Lee University of Ulsan College of Medicine, Asan Medical Center, Korea</i>	<i>Assist.Prof.THANYANAN REUNGWETWATTANA</i>
15:20-15:40		Exhibition		
		<i>Supportive care and survivor care</i>		
15:40-15:52	10000	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).	<i>Assoc.Prof.SUTHINEE ITHIMAKIN</i>	<i>Assoc.Prof.BUSYAMAS CHEWASKULYONG</i>
15:52-16:04	LBA10003	Improving Communication with Older Patients with Cancer using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT).	<i>Assoc.Prof.KOSIN WIRASORN</i>	
16:04-16:16	10005	Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer	<i>PIYAWAN TIENCHAIANANDA, M.D.</i>	
16:16-16:30		Q&A		
16:35-17:20		Symposium Pfizer: Constructing a new future in breast cancer treatment: Focusing on HR+ HER2- mBC	<i>Prof.ADAM BRUFSKY University of Pittsburgh, USA</i>	<i>TOUCH ATIVITAVAS, M.D.</i>
		End of day 1		